Nintedanib Stada (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases, including VEGFR 1‑3, PDGFR‑α/β and FGFR 1‑3. Inhibiting these receptors reduces fibroblast proliferation, extracellular matrix deposition, and new blood‑vessel formation. The resulting decrease in fibrotic tissue development and tumor vascular support underlies its therapeutic effects in pulmonary fibrosis and certain cancers.

The specific dose and dosing schedule of Nintedanib Stada are determined by the prescribing physician based on the patient’s condition, weight, renal and hepatic function, and concomitant therapies. Healthcare professionals follow the approved labeling and clinical guidelines to select an appropriate regimen for each individual.

The safety of nintedanib in pregnancy and lactation has not been established. It is classified as contraindicated or not recommended for use in pregnant or nursing women because potential risks to the fetus or infant cannot be ruled out. Women of child‑bearing potential should use effective contraception during treatment and discuss alternatives with their doctor.

To request Nintedanib Stada, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and necessary import documentation.

The primary alternative for antifibrotic therapy in idiopathic pulmonary fibrosis is pirfenidone. Both agents slow disease progression, but nintedanib targets multiple tyrosine kinases, whereas pirfenidone’s mechanism involves modulation of cytokine production and oxidative stress. Choice between them depends on patient tolerance, comorbidities, drug‑interaction profile and physician judgment.

Nintedanib Stada should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and avoid exposure to extreme temperatures. Do not refrigerate or freeze unless specifically instructed by the manufacturer.

Nintedanib Stada is taken orally, usually with food to lessen gastrointestinal discomfort. The tablets (or capsules, depending on the marketed form) are swallowed whole with a glass of water. Patients should follow the prescriber’s instructions regarding timing, dose adjustments and any required monitoring.

The most serious adverse events reported with nintedanib include severe liver injury, gastrointestinal perforation and significant bleeding. Patients should be monitored for signs of hepatic dysfunction, abdominal pain suggestive of perforation, and unusual bruising or hemorrhage. Prompt medical evaluation is essential if any of these symptoms arise.

Nintedanib Stada is contraindicated in patients with known hypersensitivity to nintedanib or any excipients, in those with active severe hepatic impairment, and in individuals with a history of gastrointestinal perforation. Caution is also advised for patients on strong anticoagulants or with uncontrolled bleeding disorders. The prescriber must assess each patient’s medical history before initiating therapy.